{
    "organizations": [],
    "uuid": "1602bc24350ddc273be723e9c0830b2a1bbdd957",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-reata-announces-top-line-data-from/brief-reata-announces-top-line-data-from-study-of-patients-with-mitochondrial-myopathies-idUSFWN1QJ1E1",
    "ord_in_thread": 0,
    "title": "Reata Announces Top-Line Data From Study Of Patients With Mitochondrial Myopathies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 1 (Reuters) - Reata Pharmaceuticals Inc:\n* REATA ANNOUNCES TOP-LINE DATA FROM THE DOSE-ESCALATION COHORTS OF THE PHASE 2 MOTOR STUDY OF OMAVELOXOLONE IN PATIENTS WITH MITOCHONDRIAL MYOPATHIES Source text for Eikon:\n ",
    "published": "2018-03-02T06:24:00.000+02:00",
    "crawled": "2018-03-02T20:22:48.051+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "reata",
        "pharmaceutical",
        "inc",
        "reata",
        "announces",
        "data",
        "cohort",
        "phase",
        "motor",
        "study",
        "omaveloxolone",
        "patient",
        "mitochondrial",
        "myopathy",
        "source",
        "text",
        "eikon"
    ]
}